15.3
Manufacturing share of global GDP in 2023
Source: World Bank Group
Danish pharmaceutical company Novo Nordisk recently announced plans to spend around $1.2 billion to build a new manufacturing facility in Odense, Denmark. The scope of the project includes a completed manufacturing facility and warehouse totaling more than 430,000 square feet.
The main facility will include on-site solar power generation. The owner wants to plant more than 4,000 trees there.
According to Novo Nordisk, the manufacturing site is designed for modularity and flexibility, allowing it to enable the production of drugs for several rare diseases such as hemophilia.
The facility will utilize “advanced technology and innovative equipment to ensure the highest quality for patients and meet the growing global demand for our life-changing medicines,” Henrik Wulff, executive vice president of product supply, quality and IT at Novo Nordisk, said in a statement.
Work is already underway on site, but a Novo Nordisk representative declined to name the contractors working on the project. Completion is scheduled for 2027.
The drugmaker has a separate project in North Carolina to expand production of its popular weight loss and diabetes medications Wegovy and Ozempic.
BE&K, based in Morrisville, North Carolina, is the construction manager for this $4.1 billion project.
The US project shares some similarities with the newly announced work in Denmark, such as the inclusion of on-site solar panels. Novo Nordisk has announced that it will seek LEED Gold certification for the facility. Completion of this facility is expected in phases beginning in 2027 and continuing through 2029.